In This Article:
As we enter January 2025, global markets are grappling with inflation concerns and political uncertainties, leading to a decline in U.S. equities and underperformance of small-cap stocks, as highlighted by the Russell 2000's dip into correction territory. In this volatile environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability to shifting economic conditions.
Top 10 High Growth Tech Companies
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Yggdrazil Group | 30.20% | 87.10% | ★★★★★★ |
| Ascelia Pharma | 76.15% | 47.16% | ★★★★★★ |
| CD Projekt | 23.18% | 27.00% | ★★★★★★ |
| Waystream Holding | 22.09% | 113.25% | ★★★★★★ |
| AVITA Medical | 33.33% | 51.81% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| Pharma Mar | 25.43% | 56.19% | ★★★★★★ |
| TG Therapeutics | 30.33% | 44.07% | ★★★★★★ |
| Elliptic Laboratories | 70.09% | 111.37% | ★★★★★★ |
| Travere Therapeutics | 29.92% | 61.97% | ★★★★★★ |
Click here to see the full list of 1223 stocks from our High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Bioneer
Simply Wall St Growth Rating: ★★★★★★
Overview: Bioneer Corporation is a biotechnology company with operations in South Korea and internationally, holding a market cap of ₩487.30 billion.
Operations: Bioneer Corporation engages in biotechnology across multiple regions, including South Korea, the Americas, Europe, Asia, and Africa. The company operates with a market capitalization of approximately ₩487.30 billion.
Bioneer, amidst a challenging fiscal year with a significant net loss of KRW 9.98 billion in Q3 2024 and an overall downturn in sales, is pivoting towards profitability with robust forecasts indicating potential annual earnings growth of 104.84%. This anticipated turnaround is underpinned by an aggressive R&D strategy, which has historically aligned well with its revenue growth projections of 26.1% per year—outpacing the Korean market's average. Recent corporate initiatives aim to deepen investor understanding and enhance corporate value, suggesting a strategic refocus that may well position Bioneer favorably within the biotech sector's competitive landscape.
-
Click here and access our complete health analysis report to understand the dynamics of Bioneer.
-
Assess Bioneer's past performance with our detailed historical performance reports.
Alphamab Oncology
Simply Wall St Growth Rating: ★★★★★☆
Overview: Alphamab Oncology is a clinical stage biopharmaceutical company focused on the research, development, manufacture, and commercialization of oncology biologics, with a market cap of HK$3.25 billion.
Operations: Alphamab Oncology generates revenue primarily from its pharmaceuticals segment, amounting to CN¥255.87 million. The company is involved in the research, development, and commercialization of oncology biologics.